Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

lead supervisor: Prof Eric o'neill, department of oncology

Co-supervisor: Prof Hua Ye, Department of Engineering Science

Commercial partner: Oxford BioMedica, Oxford


Cancer stem cells (CSCs) can drive tumorigenesis as founder elements or through malignant
cells that gain stem cell traits. CSCs are defined as slowly replicating cells, where bulk tumour
growth arises from non-CSCs. Therapeutic strategies target fast-replicating cells in bulk tumour,
as more quiescent CSCs avoid targeting and contribute to recurrence and metastatic spread by
repopulating the non-CSC compartment. Although challenging, due microenvironmental factors
and tumour plasticity between CSC and non-CSCs, targeting CSCs is critical in the search for
curative cancer treatments. The oncofetal tumor-associated antigen 5T4 (TBGP) has been
identified as a CSC marker in several malignancies. OXB have developed immunotherapies
targeting 5T4 including a Vaccinia-based vaccine (Trovax) and 5T4-directed chimeric antigen
receptor T-cells (CAR-T) (OXB-302) with positive responses in clinical trials.


Although promising, Vaccine and CAR-T cell therapies are less effective in solid tumours due to
inefficient tumour targeting, the immunosuppressive microenvironment; and tumour
heterogeneity/plasticity. Implantable biopolymer devices can deliver vaccines or CAR-T cells
directly to the surfaces of solid tumours (e.g. pancreatic cancer and melanoma), and are more
effective in tumour targeting than systemic delivery. We aim to adapt this technology to implant biopolymer scaffolds to target 5T4 expressing cells in orthotopic human tumours engrafted in immunocompromised mice. Additionally, combination of CAR-T strategies with the agonists of the STimulator of IFN Genes (STING) pathway (e.g. cyclic di-GMP) can lead to dramatic tumour regression. This is achieved though stimulation of antigens not recognized by the adoptively transferred lymphocytes that could target heterogeneous tumours or CSC and non-CSC compartments.


Thus, we propose a project to understand the role of 5T4 in CSCs, investigate bioengineering
scaffold devices that concentrate and localise 5T4-target therapies in solid tumours and combine
these with STING agonists to protect against the emergence of escape variants in vivo. We aim
to explore the feasibility of these approaches in vivo in mice and in human tissue samples. The
candidate will gain experience in cell and tumour biology, bioengineering of scaffolds and in the
design, construction and deployment of CAR-T cells in these experimental models.

MRC logo